Literature DB >> 635449

Serum bile acids in patients with viral hepatitis.

C R Pennington, P E Ross, I A Bouchier.   

Abstract

Total and individual serum bile acid concentrations were studied in 18 patients with viral hepatitis. The initial high values returned to the normal range at approximately the same time as the conventional liver function tests. Chenodeoxycholic acid was the predominant bile acid initially, but cholic acid predominated as the disease resolved. All patients had proportionately less doexycholic acid than controls. It is concluded that the measurement of serum bile acid does not provide added information of value in the management of patients with viral hepatitis.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 635449     DOI： 10.3109/00365527809179809

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN： 0036-5521            Impact factor:   2.423


  5 in total

Review 1.  Serum bile acids in hepatobiliary disease.

Authors:  I A Bouchier; C R Pennington
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

2.  Total serum bile acids and the bile acid profile as tests of liver function.

Authors:  M E Parraga; J J Kaneko
Journal:  Vet Res Commun       Date:  1985-04       Impact factor: 2.459

3.  Radioimmunoassay of primary bile salts in serum.

Authors:  Y A Baqir; J Murison; P E Ross; I A Bouchier
Journal:  J Clin Pathol       Date:  1979-06       Impact factor: 3.411

4.  Bile acids specifically increase hepatitis C virus RNA-replication.

Authors:  Patrick Chhatwal; Dorothea Bankwitz; Juliane Gentzsch; Anne Frentzen; Philipp Schult; Volker Lohmann; Thomas Pietschmann
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

5.  Natural and experimental hepatitis E virus genotype 3-infection in European wild boar is transmissible to domestic pigs.

Authors:  Josephine Schlosser; Martin Eiden; Ariel Vina-Rodriguez; Christine Fast; Paul Dremsek; Elke Lange; Rainer G Ulrich; Martin H Groschup
Journal:  Vet Res       Date:  2014-11-26       Impact factor: 3.683
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.